OpGen Series B raises $5 million

Optical genome mapping company OpGen concluded the Series B round of funding for the company, raising a total of $5 million.

Chris Anderson
MADISON, Wis.— Optical genome mapping company OpGen concluded the Series B round of funding for the company, raising a total of $5 million. The money will be used to both create additional commercial optical whole genome maps the company sells to researchers, as well as for internal research aimed at developing a commercial optical mapping tool.
 
"The funding is important to our growth, as it lets us produce more optical maps to generate revenue right now, while furthering our other model as a provider of instrumentation," says Joe Shaw, CEO of OpGen.
 
The value of the company's optical maps is that they provide detailed genetic variation information inexpensively without the need for prior sequence information, Shaw says. Current customers for the optical maps run the gamut from large pharmaceutical and biotech companies to academic and independent research organizations.
 
"These sales provide important revenue for the company while we work to commercialize the tool," Shaw adds. "We think that we can have a tool and associated disposables on the market within the next two years. But we definitely have an advantage over many start-ups since we already have a solid revenue stream."

Chris Anderson

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022